In melanoma, tumor-derived GPNMB engages Syndecan-4 on T cells to blunt antitumor immunity, with knockout studies demonstrating >50% reduction in B16F10 tumor growth (Chung et al., 2011). Here, SDC4 is linked to neoplasm.